bamlanivimab

The place of monoclonal antibodies in COVID-19 is changing. In this episode, learn about their role in prophylaxis of patients who are at high risk of complications from acquiring COVID-19 or treatment of high-risk patients who have a mild to moderate COVID-19 infection. Listen as Gregory Huhn, MD, MPHTM, discusses when and how to use monoclonal antibodies including:

• Bebtelovimab
• Cilgavimab/tixagevimab
• Sotrovimab

Presenter:

Gregory Huhn, MD, MPHTM
Associate Professor
Department of Infectious Diseases
Rush University Medical Center
Senior Director of HIV Services
Department of Infectious Diseases
Cook County Health
Chicago, Illinois

Review the downloadable slidesets at: 
https://bit.ly/3xOfu1A

Link to full program: 
https://bit.ly/3EBdf38

The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including:

• Direct-acting, small-molecule antiviral agents such as   molnupiravir, nirmatrelvir + ritonavir, and remdesivir
• Monoclonal antibody treatments such as bamlanivimab + etesevimab, casirivimab + imdevimab, cilgavimab + tixagevimab, regdanvimab, and sotrovimab

Presenter:

Arthur Kim, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Review the downloadable slidesets at:
https://bit.ly/3FXc90w
https://bit.ly/32tp2BT

Link to full program: 
https://bit.ly/3Ix8uZg

During this episode, Lynora Saxinger, MD, FRCPC, CTropMed, updates listeners on the latest Emergency Use Authorizations and guideline recommendations for optimal clinical management of COVID-19. Gain practical insights on patient identification, risk stratification, and treatment.

Key points include:

• Treatment of COVID-19 can be broken into antiviral and immune-modulating therapies
• Each agent should be used at the correct disease stage to maximize benefit
• Antiviral medications and mAbs show the greatest promise early during COVID-19, before the host immune response is mounted
• Passive immunization with mAbs can prevent infection and severe disease—and mortality—if given early to hospitalized persons
• Operational challenges to using these medications exist, but given the epidemic of unvaccinated persons, these treatments become increasingly relevant to reduce burden on healthcare systems

Presenter:

Lynora Saxinger, MD, FRCPC, CTropMed
Cochair, Scientific Advisory Group  
Alberta COVID-19 Emergency Coordination Centre  
Associate Professor
Division of Infectious Diseases
Department of Medicine  
University of Alberta
Edmonton, Alberta, Canada

Content based on an online CME program supported by an educational grant from Gilead Sciences, Inc.

Follow along with the slides at:
https://bit.ly/3BxQKtD
 

Link to full program:
https://bit.ly/3BwzdlC

In this podcast episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, and Arthur Kim, MD, discuss data on the potential use of monoclonal antibodies (mAb) for the prevention and treatment of COVID-19, including:

• Rationale for use of mAb
• Potential for resistance to mAb
• Single vs combination therapy with mAb
• Challenges in implementation of mAb as treatment or prevention
• Bamlanivimab
• Sotrovimab
• Casirivimab plus imdevimab

Link to full program, including downloadable slidesets:  https://bit.ly/3zVTwYW

Presenters: 

Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
Faculty Medicine Dentistry and Health Sciences
University of Melbourne and Royal Melbourne Hospital
Consultant Infectious Diseases Physician
Department of Infectious Diseases
Royal Melbourne Hospital and Alfred Hospital
Melbourne, Australia

Arthur Kim, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Sharon R. Lewin, AO, FRACP, PhD, FAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.

Arthur Kim, MD, has disclosed that he has served on the drug and safety monitoring board for Kintor.

In episode 17 of this series, Arthur Kim, MD, provides a brief update on the latest COVID-19 treatment options and guidelines. After the update, Dr. Kim answers questions submitted by healthcare professionals on various aspects of COVID-19.  

Presenter:

Arthur Kim, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts  

Content based on an online CME program supported by an independent educational grant from Gilead Sciences.

Link to full program:
https://bit.ly/3eDoJF0

In this episode, Part 16 of an ongoing series, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, provides a brief update on emerging COVID-19 variants and their potential impacts on vaccine efficacy. After the update, Professor Lewin answers questions submitted by healthcare professionals on various aspects of COVID-19. 

Presenter:

Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Director, The Peter Doherty Institute for Infection and Immunity
Melbourne Laureate Professor of Infectious Diseases 
University of Melbourne
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital
Melbourne, Australia

Content based on an online CME program supported by an independent educational grant from Gilead Sciences.

Link to full program:
https://bit.ly/3eDoJF0

In this episode, Part 15 of an ongoing series, Roger Paredes, MD, PhD, provides a brief update on emerging COVID-19 variants and their potential impacts on the pandemic. After the update, Dr. Paredes answers clinician questions on various aspects of COVID-19.  

Presenter:

Roger Paredes, MD, PhD
Section Chief, Infectious Diseases Department
Germans Trias i Pujol University Hospital 
Head of the Microbial Genomics Group 
IrsiCaixa AIDS Research Institute
Badalona, Catalonia, Spain

Content based on an online CME program supported by an independent educational grant from Gilead Sciences.

Link to full program:
https://bit.ly/3eDoJF0

In this episode, Part 14 of an ongoing series, Vikramjit Mukherjee, MD, provides a brief update on COVID-19 mortality trends, including the latest data on overall and in-hospital fatality rates. After the update, Dr. Mukherjee answers clinician questions on various aspects of COVID-19. 

Presenter:

Vikramjit Mukherjee, MD
Assistant Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
New York University School of Medicine
Director, Medical Intensive Care Unit
Bellevue Hospital
New York, New York

Content based on an online CME program supported by an independent educational grant from Gilead Sciences.

Link to full program:
http://bit.ly/3eDoJF0

In this episode, Part 13 of an ongoing series, Jens D. Lundgren, MD, DMSc, provides a brief update monoclonal antibody treatments for COVID-19, including the FDA Emergency Use Authorization for bamlanivimab and discusses the recently released information on COVID-19 vaccine efficacy. After the update, Professor Lundgren answers clinician questions on various aspects of COVID-19. 

Presenter:

Jens D. Lundgren, MD, DMSc
Professor
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark

Content based on an online CME program supported by an independent educational grant from Gilead Sciences.

Link to full program:
https://bit.ly/3eDoJF0

We're back after a prolonged hiatus, ready to break down the latest and greatest in the medical literature.  Today's episode will get you caught up on the newest treatments for COVID-19.  We promise to talk about something else next time :)

If you want to skip all the banter about Baby Yoda and politics, go to 8:36.

Remdesivir for COVID-19 Final Report

Tocilizumab for Hospitalized COVID-19 Patients

Bamlanivimab

Pfizer Vaccine

Moderna Vaccine

Music from https://filmmusic.io
"Sneaky Snitch" by Kevin MacLeod (https://incompetech.com)
License: CC BY (http://creativecommons.org/licenses/by/4.0/)

Back in June, Dr. Gregory Huhn and Dr. Ajay Nirula--two highly accomplished medical experts on the front lines of the fight against COVID-19--joined us to discuss all things pandemic. They return with the latest on the worsening conditions throughout the country and the highly promising news on the vaccine and treatment fronts, providing answers to our questions about a potential ramp-up of testing and tracing, science skeptics, President-Elect Biden’s likely approach, President Trump’s post-treatment steroid high (and Dr. Huhn’s creative diagnosis) and how and when we can get back to normal. We also make Dr. Nirula pronounce the name of the antibody-therapy drug he and Dr. Huhn helped develop--as published in the New England Journal of Medicine--and suggest a few alternative monikers.